EUSA Pharma

company

About

EUSA Pharma is a pharmaceutical company developing and licensing late-stage oncology, pain control, and critical care products.

  • 51 - 100

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$18.60M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Mar 1, 2006
Number Of Employee
51 - 100
Operating Status
Active

Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA.

Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole®

EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016.

EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands.

In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$40.23M
EUSA Pharma has raised a total of $40.23M in funding over 2 rounds. Their latest funding was raised on Jun 28, 2007 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 28, 2007 Series Unknown $9.10M 1 Detail
Nov 7, 2006 Series Unknown $18.60M 4 Detail
Dec 13, 2005 Series Unknown $12.53M 1 Detail

Investors

Number of Lead Investors
Number of Investors
5
EUSA Pharma is funded by 5 investors. Fort Mason Capital and Oppenheim Pramerica Asset Management are the most recent investors.
Investor Name Lead Investor Funding Round
Fort Mason Capital Series Unknown
Oppenheim Pramerica Asset Management Series Unknown
Little Gem Life Sciences Capital Management Series Unknown
Alexandra Investment Management Series Unknown
Downsview Capital Series Unknown